CD34

CD34

CD34 Overview

Molecule Name
Hematopoietic progenitor cell antigen CD34
Synonyms
CD34,RP11-328D5.2
Drug Development Progress
Drugs in Clinical Trials12
Approved Drugs1
Highest Development StageApproved
Target Synonym
CD34,CD34 Molecule,CD34 Antigen,Hematopoietic Progenitor Cell Antigen CD34,Antigens, CD34
Background
CD34 molecule is a cluster of differentiation molecule present on certain cells within the human body. It is a cell surface glycoprotein and functions as a cell-cell adhesion factor. It may also mediate the attachment of stem cells to bone marrow extracellular matrix or directly to stromal cells. As a ~ 110 kDa monomeric cell surface antigen, CD34 is highly glycosylated with nine potential N-linked and numerous potential O-linked glycosylation sites in its extracellular domain. The CD34 protein is a member of a family of single-pass transmembrane sialomucin proteins that show expression on early hematopoietic and vascular-associated tissue. CD34 is also an important adhesion molecule and is required for T cells to enter lymph nodes. It is expressed on lymph node endothelia whereas the L-selectin to which it binds is on the T cell. It was indicated that CD34 is a phosphorylation target for activated PKC, and couples to the hematopoietic adapter protein CrkL, which were involved in CD34 signaling pathways. CD34 is abberantly expressed in many kinds of tumors and is implicated in leukemogenesis.

CD34 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
CLBS-12CLBS-12Phase 2 ClinicalCaladrius Biosciences Inc
Atherosclerosis; Ischemia; Thromboangiitis Obliterans
Details
Retroviral ADA-transduced CD34+ cells (NHGRI/UCLA)Phase 2 ClinicalUcla Biomedical Library
Adenosine deaminase deficiency
Details
CD34+ bone marrow stem cells (University of California)Phase 2 ClinicalThe University Of California Davis
Diabetic Retinopathy; Macular Degeneration; Retinal Vein Occlusion; Retinitis Pigmentosa
Details
Autologous peripheral blood stem cell therapy (CellProthera)Phase 2 ClinicalCellprothera
Myocardial Infarction
Details
CD34 stem cell therapy (LA Childrens Hospital)Phase 2 ClinicalChildren'S Hospital Of Los Angeles
Heart Failure; HIV Infections
Details
Stem cell therapeutics (ExCellThera)ECT-002; ECT-003; ECT-005; UM171 + UM092; UM171 + UM390Phase 2 ClinicalExcellthera Inc
Leukemia, Myeloid, Acute
Details
Lentiviral vector transduced CD34+ cells TherapyPhase 2 ClinicalGreat Ormond Street Hospital For Children Nhs Foundation Trust
Granulomatous Disease, Chronic
Details
Cord blood stem cells(Tatcitus Therapeutics/Mount Sinai Health System)HSC-100Phase 1 ClinicalIcahn School Of Medicine At Mount Sinai, Tatcitus Therapeutics
Hematologic Neoplasms; Hodgkin Disease; Leukemia; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
shRNA-Modified CD34 Cell TherapyKL-AI20Phase 1 ClinicalKanglin Biotech (Hangzhou) Co Ltd
HIV Infections
Details
Alpha-galactosidase A stem cell therapy (University Health Network/Ozmosis)Phase 1 ClinicalUniversity Health Network (Uhn)
Fabry Disease
Details
Autologous CD34+ Cells Therapy (Zhongji Zhiyao (Nanjing) Biotechnology Co Ltd)GMCN-508APhase 1 ClinicalZhongji Zhiyao (Nanjing) Biotechnology Co Ltd
alpha-Thalassemia
Details
Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion(German Cancer Research Center)Phase 1 ClinicalGerman Cancer Research Center (Dkfz)
Leukemia, Myeloid, Acute
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Anti-CD34 mab-sirolimus (OrbusNeich)ApprovedOrbusneichCoronary RestenosisOrbusneich2013-01-01
Coronary Artery Disease; Coronary Restenosis
Details